{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Blood+Protein+Disorders", "query": { "condition": "Blood Protein Disorders" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 3033, "total_pages": 304, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Blood+Protein+Disorders&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-22T07:45:47.963Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01815749", "title": "Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Grade III Lymphomatoid Granulomatosis", "Cutaneous B-cell Non-Hodgkin Lymphoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Intraocular Lymphoma", "Nodal Marginal Zone B-cell Lymphoma", "Post-transplant Lymphoproliferative Disorder", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Small Lymphocytic Lymphoma", "Refractory Hairy Cell Leukemia", "Small Intestine Lymphoma", "Splenic Marginal Zone Lymphoma", "Testicular Lymphoma", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells", "type": "BIOLOGICAL" }, { "name": "autologous hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2013-10-08", "completion_date": "2027-05-31", "has_results": false, "last_update_posted_date": "2026-06-25", "last_synced_at": "2026-07-22T07:45:47.963Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01815749" }, { "nct_id": "NCT00720785", "title": "Natural Killer Cells and Bortezomib to Treat Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Myeloid Leukemia (CML)", "Pancreatic Ca", "Colon/Rectal Ca", "Multiple Myeloma", "Carcinoma, Non-Small -Cell Lung" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "NK cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 35, "start_date": "2008-08-01", "completion_date": "2021-04-06", "has_results": false, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-07-22T07:45:47.963Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00720785" }, { "nct_id": "NCT02628704", "title": "Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" }, { "name": "Placebo (for selinexor)", "type": "DRUG" }, { "name": "carfilzomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Karyopharm Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2015-12", "completion_date": "2018-06", "has_results": false, "last_update_posted_date": "2023-01-26", "last_synced_at": "2026-07-22T07:45:47.963Z", "location_count": 2, "location_summary": "West Hollywood, California • Cary, North Carolina", "locations": [ { "city": "West Hollywood", "state": "California" }, { "city": "Cary", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02628704" }, { "nct_id": "NCT01998633", "title": "Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hemophagocytic Lymphohistiocytosis", "Chronic Active Epstein-Barr Virus Infection", "Chronic Granulomatous Disease", "HIGM-1", "Leukocyte Adhesion Deficiency", "IPEX" ], "interventions": [ { "name": "Hematopoietic Stem Cell Transplant", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Months", "maximum_age": "45 Years", "sex": "ALL", "summary": "4 Months to 45 Years" }, "enrollment_count": 47, "start_date": "2013-12", "completion_date": "2016-12", "has_results": true, "last_update_posted_date": "2022-12-08", "last_synced_at": "2026-07-22T07:45:47.963Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01998633" }, { "nct_id": "NCT04014764", "title": "Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Acute Myelogenous Leukemia", "Multiple Myeloma", "Myelodysplastic Syndromes", "Lymphoma", "Acute Lymphoblastic Leukemia", "Chronic Myelogenous Leukemia", "Myeloproliferative Neoplasm" ], "interventions": [ { "name": "This is a non-interventional study", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Notable Labs", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 119, "start_date": "2019-12-15", "completion_date": "2022-03-31", "has_results": false, "last_update_posted_date": "2022-04-05", "last_synced_at": "2026-07-22T07:45:47.963Z", "location_count": 11, "location_summary": "Bakersfield, California • San Luis Obispo, California • Grand Junction, Colorado + 8 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "San Luis Obispo", "state": "California" }, { "city": "Grand Junction", "state": "Colorado" }, { "city": "Ocala", "state": "Florida" }, { "city": "Orange City", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04014764" }, { "nct_id": "NCT03710421", "title": "CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Plasma Cell Myeloma", "Refractory Plasma Cell Myeloma" ], "interventions": [ { "name": "CS1-CAR T Therapy", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Leukapheresis", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2019-04-23", "completion_date": "2027-02-23", "has_results": false, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-07-22T07:45:47.963Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03710421" }, { "nct_id": "NCT04314752", "title": "Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Myeloma" ], "interventions": [], "intervention_types": [], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 4000, "start_date": "2020-09-01", "completion_date": "2026-05-30", "has_results": false, "last_update_posted_date": "2025-09-25", "last_synced_at": "2026-07-22T07:45:47.963Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04314752" }, { "nct_id": "NCT01985126", "title": "An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Daratumumab 16 mg/kg (Part 1)", "type": "DRUG" }, { "name": "Daratumumab 8 mg/kg (Part 1)", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Daratumumab (Part 2)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 124, "start_date": "2013-09-27", "completion_date": "2017-05-30", "has_results": true, "last_update_posted_date": "2018-06-25", "last_synced_at": "2026-07-22T07:45:47.963Z", "location_count": 15, "location_summary": "Duarte, California • Los Angeles, California • Atlanta, Georgia + 12 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT01985126" }, { "nct_id": "NCT03003533", "title": "A Gene Transfer Study for Hemophilia A", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hemophilia A" ], "interventions": [ { "name": "SPK-8011", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Spark Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 25, "start_date": "2017-01-26", "completion_date": "2023-12-05", "has_results": true, "last_update_posted_date": "2024-12-30", "last_synced_at": "2026-07-22T07:45:47.963Z", "location_count": 11, "location_summary": "Sacramento, California • Gainesville, Florida • Boston, Massachusetts + 7 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Madison", "state": "Mississippi" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03003533" }, { "nct_id": "NCT00697684", "title": "Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "Myelodysplastic Syndrome", "Acute Lymphocytic Leukemia", "Relapsed/Refractory Chronic Lymphocytic Leukemia", "Relapsed/Refractory Non Hodgkin's Lymphoma", "Hodgkins Disease", "Relapsed Refractory Multiple Myeloma" ], "interventions": [ { "name": "Antithymocyte Globulin", "type": "DRUG" }, { "name": "Clofarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Beth Israel Deaconess Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 29, "start_date": "2008-06", "completion_date": "2023-11", "has_results": false, "last_update_posted_date": "2023-11-28", "last_synced_at": "2026-07-22T07:45:47.963Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00697684" } ] }